Sanofi Aventis-backed biopharma company Regulus Therapeutics preps for its anticipated IPO.
Sanofi Aventis-backed biopharmaceutical company Regulus Therapeutics is prepping for an IPO.
The San Diego-based company has filed a registration statement with the Securities and Exchange Commission to list on Nasdaq with the ticker symbol RGLS. Acting as joint book-runners are Lazard Capital Markets, Cowen & Co. and BMO Capital Markets. Needham & Company and Wedbush PacGrow Life Sciences are co-managers.
The company’s principal stockholders are parent companies Alnylam Pharamaceuticals and Isis Pharmaceuticals, which own 44.1% and 45.2% of the…
